Molecular targeting of renal cell carcinoma by an oral combination

The 5-year survival rate of patients with metastatic renal cell carcinoma (mRCC) is <12% due to treatment failure. Therapeutic strategies that overcome resistance to modestly effective drugs for mRCC, such as sorafenib (SF), could improve outcome in mRCC patients. SF is terminally biotransformed...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncogenesis
मुख्य लेखकों: Jordan, Andre R., Wang, Jiaojiao, Yates, Travis J., Hasanali, Sarrah L., Lokeshwar, Soum D., Morera, Daley S., Shamaladevi, Nagarajarao, Li, Charles S., Klaassen, Zachary, Terris, Martha K., Thangaraju, Muthusamy, Singh, Amar B., Soloway, Mark S., Lokeshwar, Vinata B.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group UK 2020
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7237463/
https://ncbi.nlm.nih.gov/pubmed/32427869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-020-0233-0
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन